- [Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
May 11, 2026
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Flexible Endoscope Market size & share revenue was valued at approximately USD 12.7 Billion in 2025 and is expected to reach USD 13.5 Billion in 2026 and is expected to reach around USD 22.7 Billion by 2035, at a CAGR of 6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Olympus Corporation, Cook Medical Inc., Becton Dickinson and Company, Boston Scientific Corporation, Cantel Medical Corporation, Conmed Corporation, B. Braun SE, EndoMed Systems GmbH, Firefly Global, Fujifilm Holdings Corporation, H.W.Andersen Products Ltd., Hoya Corporation, Intuitive Surgical Inc., Karl Storz SE & Co. KG, Machida Endoscope Co. Ltd, Ambu A/S and others.
Austin, TX, USA, May 11, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” in its research database.
According to the latest research study, the global Flexible Endoscope Market was valued at approximately USD 12.7 billion in 2025 and is expected to reach USD 13.5 billion in 2026, with a projected value of around USD 22.7 billion by 2035, at a compound annual growth rate (CAGR) of about 6% during the forecast period from 2026 to 2035.
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/request-customization?reportId=1002Flexible Endoscope Market 2026 – 2035
Flexible Endoscope Market Revenue and Trends
A flexible endoscope is a medical tool that looks inside the body, finds problems, and treats them without making big cuts or through small openings.It has a long, thin, and flexible insertion tube that contains a light source, a high-resolution camera or a fiber-optic imaging system, and one or more working channels for instruments used in biopsy, suction, irrigation, or therapeutic procedures.. Flexible endoscopes' ability to bend and navigate through complex anatomical pathways makes them perfect for examining different parts of the body, such as the gastrointestinal tract, respiratory system, urinary tract, and other delicate structures. They are involved with many procedures including gastroscopy, colonoscopy, bronchoscopy, and cystoscopy and are central to the whole process of minimally invasive diagnostics and treatment that depends on real-time visualization with fair patient comfort level, quicker recovery, and lower risk compared to traditional surgical techniques. The market growth is driven by several factor such as increasing prevalence of cancer, growing product launch and increasing investment in emerging markets by the key market players.
Story Continues
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/request-sample?reportId=1002
What factors significantly contribute to the growth of the flexible endoscope market?
The flexible endoscopes market is experiencing significant growth due to an amalgamation of various factors like clinical, technological, economic, and regulatory which in turn are increasing the number of procedures and speeding up the adoption of equipment across the different healthcare sectors.
The global burden of diseases affecting the gastrointestinal and respiratory systems which are very painful and expensive to treat as they include conditions like GERD, colorectal cancer, inflammatory bowel disease, COPD, and lung infections is also one of the main factors that is driving the endoscope market. Controlling and monitoring the diseases through endoscopic means requires frequent diagnosis and monitoring. Besides this, the industry is also turning to the less challenging method of open surgeries, i.e. flexible endoscopy, to do less harm to the patients and cut hospital stays and treatment costs.
In addition, medical science is advancing rapidly in technology, which is also a major factor driving the endoscope market. The introduction of high-definition and 4K imaging, along with better visualization techniques, AI-powered lesion detection, and advanced tissue imaging (optical biopsy), improves diagnostic accuracy and builds clinical confidence, making hospitals more likely to upgrade or replace their old systems. More focus on infection control and patient safety has also led to faster adoption of single-use flexible endoscopes and endoscopes with disposable parts, thus creating new revenue streams and penetrating high-risk procedures more effectively.
(A free sample of the Flexible Endoscope report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
The updated report for 2026 includes an introduction, an overview, and an in-depth industry analysis. Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2026 Includes tables and figures that have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Healthcare Foresights (HEALTHCARE FORESIGHTS) research methodology
Request a Customized Copy of the Flexible Endoscope Market Report @https://www.healthcareforesights.com/reports/flexible-endoscope-market
Segment Insight
By Product
The gynecology endoscopes segment is growing at a significant rate over the projected period. The growing number of gynecological disorders, such as uterine fibroids, endometriosis, polycystic ovary syndrome (PCOS), and cancers of the cervix and uterus, is the main reason for the growth of this market. Patients suffering from such diseases invariably require the diagnostic and therapeutic endoscopic interventions of the highest order. As awareness of women’s health issues grows and screening and early intervention programs expand, mere reliance on flexible endoscopes for procedures translates into a large volume of procedures and, consequently, sales of the related equipment.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Key questions answered in this report:
What is the size of the Flexible Endoscope market, and what is its expected growth rate? What are the primary driving factors that push the Flexible Endoscope market forward? What are the Flexible Endoscope Industry's top companies? What are the different categories that the Flexible Endoscope Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do key players play? What is the procedure for getting a free copy of the sample report for the Flexible Endoscope market and company profiles?
Buy Now Flexible Endoscope Market Report @ https://www.healthcareforesights.com/checkout/1002
Key Offerings:
Market Share, Size & Forecast by Revenue | 2026−2035 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Insights
The flexible endoscope market has been dominated by North America. The North America region has also been supported by advanced healthcare infrastructure, government initiatives that are conducive to healthcare, and optimum treatment coverage.
Besides, the Asia-Pacific market has the highest growth rate in the flexible endoscope market. The major influencing factor for this upsurge is the heavy burden of the target illnesses, and the expectation of a significant patient group is also going to help the growth of the area. The healthcare infrastructure in the region is improving, with increased investment from market players primarily driven by the booming demand for medical devices in the APAC region, leading to a certain degree of growth.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
We customize your report to align with your specific research requirements. Inquire with our sales team about customizing your report.)
Still Looking for More Information? Do you want data for inclusion in magazines, case studies, research papers, or media?
Email Directly Here with Detailed Information: support@custommarketinsights.com
Browse the full “Flexible Endoscope Market Size, Trends and Insights By Product (Bronchoscopes, Laparoscopes, Otoscopes, Laryngoscopes, Cystoscopes, Ureteroscopes, Arthroscopes, Nasopharyngoscopes, Neuroendoscopes, Rhinoscopes, Gastrointestinal Endoscopes, Hysteroscopes, Gynecology Endoscopes), By End Use (Hospitals, Outpatient Facilities), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2026 – 2035” Report at https://www.healthcareforesights.com/reports/flexible-endoscope-market
Report Scope
Feature of the Report Details Market Size in 2026 USD 13.5 billion Projected Market Size in 2035 USD 22.7 billion Market Size in 2025 USD 12.7 billion CAGR Growth Rate 6% CAGR Base Year 2025 Forecast Period 2026-2035 Key Segment By Product, End Use and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research.
Recent Developments
In August 2024, KARL STORZ United States, a global leader in Operating Room (OR) integration, teamed up with FUJIFILM Healthcare Americas Corporation (Fujifilm), a major maker of endoscopic imaging and endosurgical products, to provide a wide range of solutions for both endoscopists and surgeons. The two companies will together promote Fujifilm’s exceptional flexible gastrointestinal (GI) endoscopes and KARL STORZ’s unmatched OR integration solutions. The partnership between Fujifilm and KARL STORZ will help upgrade surgical ORs, routine and interventional hospital GI suites, and ambulatory surgery centers (ASCs) with innovative OR integration and state-of-the-art flexible endoscopes in areas where most GI and surgical OR procedures are done. (Source: https://www.biopharmaapac.com/news/77/5181/karl-storz-and-fujifilm-healthcare-partner-to-enhance-gi-endoscopy-and-or-integration.html)
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Spectacular Deals
Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. A personalized market brief by the author.
Browse More Related Reports:
Henatologic Malignancies Testing Market
US Clinical Trial Supplies Market
Ear Health Market
Fluorescent In Situ Hybridization Probe Market
Laboratory Equipment Services Market
Synthetic Bone Graft Substitutes Market
Japan Epigenetics Market
US Cell-Based Assays Market
Therapeutic Plasma Exchange Market
Therapeutic Apheresis MarketNorth America Flexible Endoscope Market Size 2025 to 2035 (USD Billion)
List of the prominent players in the Flexible Endoscope Market:
Olympus Corporation Cook Medical Inc. Becton Dickinson and Company Boston Scientific Corporation Cantel Medical Corporation Conmed Corporation B. Braun SE EndoMed Systems GmbH Firefly Global Fujifilm Holdings Corporation H.W. Andersen Products Ltd. Hoya Corporation Intuitive Surgical Inc. Karl Storz SE & Co. KG Machida Endoscope Co. Ltd Ambu A/S Others
The Flexible Endoscope Market is segmented as follows:
By Product
Bronchoscopes Laparoscopes Otoscopes Laryngoscopes Cystoscopes Ureteroscopes Arthroscopes Nasopharyngoscopes Neuroendoscopes Rhinoscopes Gastrointestinal Endoscopes Hysteroscopes Gynecology Endoscopes
By End Use
Hospitals Outpatient Facilities
Click Here to Get a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Regional Coverage:
North America
U.S. Canada Mexico Rest of North America
Europe
Germany France U.K. Russia Italy Spain Netherlands Rest of Europe
Asia Pacific
China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa
Latin America
Brazil Argentina Rest of Latin America
This Flexible Endoscope Market Research/Analysis Report Contains Answers to the following Questions.
Which Trends Are Causing These Developments? Who Are the Global Key Players in This Flexible Endoscope Market? What are the company profiles, product information, and contact details for these key players? What Was the Global Market Status of the Flexible Endoscope Market? What Was the Capacity, Production Value, Cost, and PROFIT of the Flexible Endoscope Market? What Is the Current Market Status of the Flexible Endoscope Industry? What's the market's competition in this industry, both company-wise and country-wise? What is the market analysis of the flexible endoscope market, considering its applications and types? What Are Projections of the Global Flexible Endoscope Industry Considering Capacity, Production, and Production Value? What Will Be the Estimate of Cost and Profit? What Will Be the Market Share, Supply, and Consumption? What about imports and exports? What is a Flexible Endoscope market chain analysis of upstream raw materials and downstream industries? What is the economic impact on the Flexible Endoscope industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are the Market Dynamics of the Flexible Endoscope Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for the Flexible Endoscope Industry?
Click Here to Access a Free Sample Report of the Global Flexible Endoscope Market @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
Reasons to Purchase Flexible Endoscope Market Report
The Flexible Endoscope Market Report gives both qualitative and quantitative analysis of the market by looking at economic and non-economic factors. Flexible Endoscope: The market report outlines the market value (in USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Flexible Endoscope Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprise a company overview, company insights, product benchmarking, and SWOT analysis for the major market players. Recent developments, including growth opportunities and drivers, as well as challenges and restraints in both emerging and developed regions, shape the industry's current and future market outlook. Flexible Endoscope Market: Includes in-depth market analysis from various perspectives through Porter's five forces analysis and offers an overview of the market through the value chain.
Reasons for the Research Report
The study provides a thorough overview of the global Flexible Endoscope market. Compare your performance to that of the market as a whole.
Aim to maintain competitiveness while innovations from established leaders drive market growth.
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
What does the report include?
Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Flexible Endoscope market analysis.
The report covers the competitive environment of current and potential participants in the Flexible Endoscope market, along with their strategic product development ambitions.
This study conducts a qualitative and quantitative analysis of the Flexible Endoscope market based on the component, application, and industry vertical. Additionally, the report provides comparable data for the key regions.
The report provides actual market sizes and forecasts for each segment mentioned above.
Who should buy this report?
Participants and stakeholders in the worldwide flexible endoscope market should find this report useful. The research will be useful to all market participants in the Flexible Endoscope industry.
Managers in the Flexible Endoscope sector are interested in publishing up-to-date and projected data about the worldwide Flexible Endoscope market.
Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Flexible Endoscope products' market trends.
Analysts, researchers, educators, strategy managers, and government organizations seek market insights to develop plans.
Request a Customized Copy of the Flexible Endoscope Market Report @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
About Healthcare Foresights:
Healthcare Foresights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains.
Healthcare Foresights is a one-stop solution for data collection and investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts advise clients on aspects such as strategies for future estimation, forecasting, opportunities to grow, and consumer surveys.
Follow Us: LinkedIn | Twitter | Facebook | Instagram
Contact Us:
Frank Gittens
CMI Consulting LLC
701 Tillery Street Unit 12-1333
Austin, Texas 78702
United States
USA: +1 737-734-2707
APAC: +91 20 46022736
WhatsApp No : +1 801 639 9061
Email: support@healthcareforesights.com
Blog: https://www.healthcareforesights.com/
Buy this Premium Flexible Endoscope Research Report | Fast Delivery Available - [220+ Pages] @ https://www.healthcareforesights.com/reports/flexible-endoscope-market
View Comments
- Looking for a Growth Stock? 3 Reasons Why Intuitive Surgical (ISRG) is a Solid Choice
May 11, 2026
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.
That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.
However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Intuitive Surgical, Inc. (ISRG) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
While there are numerous reasons why the stock of this company is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings Growth
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Intuitive Surgical is 14.3%, investors should actually focus on the projected growth. The company's EPS is expected to grow 16.5% this year, crushing the industry average, which calls for EPS growth of 12.3%.
Cash Flow Growth
While cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.
Right now, year-over-year cash flow growth for Intuitive Surgical is 15.8%, which is higher than many of its peers. In fact, the rate compares to the industry average of 0%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 19.5% over the past 3-5 years versus the industry average of 7.5%.
Story Continues
Promising Earnings Estimate Revisions
Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
There have been upward revisions in current-year earnings estimates for Intuitive Surgical. The Zacks Consensus Estimate for the current year has surged 5.1% over the past month.
Bottom Line
Intuitive Surgical has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions Intuitive Surgical well for outperformance, so growth investors may want to bet on it.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet
May 11, 2026
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Intuitive Surgical, Inc. (ISRG) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Intuitive Surgical currently has an average brokerage recommendation (ABR) of 1.71, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.71 approximates between Strong Buy and Buy.
Of the 31 recommendations that derive the current ABR, 20 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 64.5% and 6.5% of all recommendations.
Brokerage Recommendation Trends for ISRGBroker Rating Breakdown Chart for ISRG
Check price target & stock forecast for Intuitive Surgical here>>>
The ABR suggests buying Intuitive Surgical, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Story Continues
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Should You Invest in ISRG?
In terms of earnings estimate revisions for Intuitive Surgical, the Zacks Consensus Estimate for the current year has increased 5.1% over the past month to $10.4.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Intuitive Surgical. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for Intuitive Surgical may serve as a useful guide for investors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Is It Time To Reconsider Intuitive Surgical (ISRG) After Recent Share Price Weakness?
May 9, 2026
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Wondering if Intuitive Surgical at around US$453 per share is still worth your attention, or if the stock price already reflects most of the opportunity? The stock has been relatively flat over the past week with a 0.9% decline and is roughly unchanged over 30 days. Year to date it is down 19.3%, the 1 year return sits at a 15.7% decline, and the 3 year and 5 year returns are 49.4% and 65.8% respectively. Recent share price moves come as investors continue to assess the company's position in robotic assisted surgery, regulatory developments and broader sentiment toward higher growth healthcare stocks. These factors help frame whether current levels reflect caution about future growth, enthusiasm about long term adoption of its systems, or simply resetting expectations. On Simply Wall St's valuation checks, Intuitive Surgical currently scores 1 out of 6, as shown in this valuation score. Next up is a closer look at how different valuation methods assess the stock today and how a more complete framework can help you interpret those signals with more confidence.
Intuitive Surgical scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Intuitive Surgical Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the company may generate in the future and discounting those amounts back to today using a required rate of return.
For Intuitive Surgical, the model used is a 2 Stage Free Cash Flow to Equity approach. It works off last twelve months free cash flow of about $2.3b. Analysts provide explicit free cash flow estimates for the next few years, and Simply Wall St then extrapolates those numbers further out. Under this set of assumptions, projected free cash flow in 2030 is about $6.1b, with each year in between discounted back to today to reflect risk and the time value of money.
Adding up the discounted cash flows produces an estimated intrinsic value of about $403.53 per share. Against a current share price around $453, the DCF suggests Intuitive Surgical trades at roughly a 12.4% premium to this estimate, so the stock screens as overvalued on this model.
Result: OVERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Intuitive Surgical may be overvalued by 12.4%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities.
Story Continues
ISRG Discounted Cash Flow as at May 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Intuitive Surgical.
Approach 2: Intuitive Surgical Price vs Earnings
For a profitable company like Intuitive Surgical, the P/E ratio is a useful way to think about value because it links what you pay for each share to the earnings that share currently generates. Higher expected earnings growth and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to align with a lower, more conservative P/E.
Intuitive Surgical currently trades on a P/E of about 53.9x. That is well above the Medical Equipment industry average of roughly 24.1x and the peer average of about 25.8x, which signals that investors are willing to pay a premium for its earnings.
Simply Wall St’s Fair Ratio for Intuitive Surgical is 32.1x. This is a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, risk profile, industry and market cap, rather than a simple comparison with peers. Because it adjusts for these company specific features, it can give you a more tailored reference point than a broad industry or peer average. Comparing the Fair Ratio of 32.1x to the current P/E of 53.9x, the stock screens as overvalued on this metric.
Result: OVERVALUEDNasdaqGS:ISRG P/E Ratio as at May 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your Intuitive Surgical Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St’s Community page where you (and millions of other investors) connect your view of Intuitive Surgical to a full forecast and Fair Value, then compare that to today’s share price.
A Narrative is your story for a company, written in numbers as well as words. It covers how you see future revenue, earnings and margins, and what you think a fair value is based on those assumptions.
Instead of only looking at a DCF or P/E in isolation, a Narrative ties Intuitive Surgical’s business story to a financial model and then to a Fair Value that updates automatically when new news, earnings or regulatory developments are added to the platform.
For example, one Intuitive Surgical Narrative on Simply Wall St currently has a Fair Value of about US$325.55. Another sits at about US$750.00. This shows how two investors can look at the same company, plug different growth, margin and discount rate assumptions into their stories, and reach very different views on whether the current price feels high, low or about right for them.
For Intuitive Surgical however we will make it really easy for you with previews of two leading Intuitive Surgical Narratives:
🐂 Intuitive Surgical Bull Case
Fair value: US$532.46 per share
Implied valuation gap vs last close: about 14.8% below this narrative fair value
Revenue growth assumption: 12%
This narrative leans on the scale of the da Vinci installed base and the high share of recurring instruments, services and software revenue as key strengths. It highlights a wide moat built around hospital dependence on ongoing parts, maintenance and upgrades to keep systems in use. The author views Intuitive Surgical as a high quality business and frames return expectations in terms of whether the entry price lines up with required annual returns.
🐻 Intuitive Surgical Bear Case
Fair value: US$325.55 per share
Implied valuation gap vs last close: about 39.3% above this narrative fair value
Revenue growth assumption: 12%
This narrative focuses on catalysts such as broader procedure adoption, recurring consumables and service revenue, and product upgrades, but questions how much of this is already reflected in the share price. It sets out industry tailwinds like demand for minimally invasive surgery alongside headwinds such as high system costs, competition, and regulatory and reimbursement risk. The author flags valuation sensitivity as a key issue, noting that if growth or margins fall short of expectations the current pricing could be at risk of a sharp correction.
If you want to go deeper than these previews and see how other investors are joining the dots between growth, margins and valuation for Intuitive Surgical, See what the community is saying about Intuitive Surgical.
Do you think there's more to the story for Intuitive Surgical? Head over to our Community to see what others are saying!NasdaqGS:ISRG 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ISRG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Here is What to Know Beyond Why Intuitive Surgical, Inc. (ISRG) is a Trending Stock
May 8, 2026
Intuitive Surgical, Inc. (ISRG) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this company have returned -0.3%, compared to the Zacks S&P 500 composite's +11% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has lost 0.3%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Intuitive Surgical is expected to post earnings of $2.48 per share for the current quarter, representing a year-over-year change of +13.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.
For the current fiscal year, the consensus earnings estimate of $10.4 points to a change of +16.5% from the prior year. Over the last 30 days, this estimate has changed +5.1%.
For the next fiscal year, the consensus earnings estimate of $11.71 indicates a change of +12.6% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed +3.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Intuitive Surgical.
Story Continues
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS12-month consensus EPS estimate for ISRG
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Intuitive Surgical, the consensus sales estimate for the current quarter of $2.81 billion indicates a year-over-year change of +15%. For the current and next fiscal years, $11.72 billion and $13.18 billion estimates indicate +16.5% and +12.4% changes, respectively.
Last Reported Results and Surprise History
Intuitive Surgical reported revenues of $2.77 billion in the last reported quarter, representing a year-over-year change of +23%. EPS of $2.5 for the same period compares with $1.81 a year ago.
Compared to the Zacks Consensus Estimate of $2.61 billion, the reported revenues represent a surprise of +6.24%. The EPS surprise was +20.19%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Intuitive Surgical (ISRG): The Best Healthcare AI Stock to Buy According to Analysts
May 5, 2026
Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the
8 Best Healthcare AI Stocks to Buy According to Analysts.
On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental beat,” driven by procedure growth and system placements.
A day earlier, Baird raised its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $610 from $575 and kept an Outperform rating. The firm updated its model after the company’s beat-and-raise quarter, though it cautioned that broader MedTech sentiment could weigh on the stock.
On April 21, 2026, Intuitive Surgical reported Q1 adjusted EPS of $2.50, well above consensus estimates of $2.11, while revenue rose to $2.77 billion from expectations of $2.62 billion. Worldwide procedures across the da Vinci Surgical System and Ion System platforms grew about 17% year over year. Da Vinci procedures increased approximately 16%, while Ion procedures rose around 39%. The company placed 431 da Vinci systems during the quarter, up from 367 a year earlier, including 232 da Vinci 5 systems compared to 147 in the prior-year period. It also placed 52 Ion systems, up from 49 last year.Intuitive Surgical (ISRG): The Best Healthcare AI Stock to Buy According to Analysts
For full-year 2026, Intuitive Surgical expects da Vinci procedure growth of about 13.5% to 15.5%, a non-GAAP gross margin of 67.5% to 68.5% of revenue, and operating expense growth of 11% to 14%. The margin outlook includes an estimated 1% revenue impact from tariffs.
Intuitive Surgical, Inc. (NASDAQ:ISRG) develops robotic-assisted surgical systems and related technologies aimed at expanding access to minimally invasive care globally.
While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Assessing Intuitive Surgical (ISRG) Valuation As Recent Share Price Weakness Meets Strong Long Term Returns
May 4, 2026
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Why Intuitive Surgical stock is drawing attention now
Intuitive Surgical (ISRG) is back in focus after a choppy stretch for the stock, prompting investors to reassess how its current share price lines up with recent returns and the scale of its surgical robotics business.
See our latest analysis for Intuitive Surgical.
At a share price of US$457.78, Intuitive Surgical has seen a 1-day share price return close to flat, a 7-day share price return of a 2.8% decline, and a year-to-date share price return of an 18.54% decline. Its 3-year total shareholder return of 51.04% and 5-year total shareholder return of 64.51% point to much stronger longer term compounding for investors, suggesting recent momentum has faded even as the longer run story remains intact.
If Intuitive Surgical’s recent swings have you reassessing your watchlist, this could be a moment to scan other robotics and automation opportunities using our 34 robotics and automation stocks
So with Intuitive Surgical posting steady revenue and net income growth, yet trading at an intrinsic premium and at a discount to some analyst targets, should you see current levels as a fresh entry point or a sign that markets already price in future growth?
Most Popular Narrative: 14% Undervalued
Tokyo’s widely followed narrative pegs Intuitive Surgical’s fair value at $532.46, above the recent $457.78 close. This frames the stock as modestly undervalued on that lens.
A Growing Installed Base is good but the Recurring Revenue makes the Difference
Today, 9,539 da Vinci systems are installed worldwide, with an annual growth rate of 15.1%. Each year, these systems perform approximately 2.2 million procedures, a number that has been growing at a rate of 22.2% per year.
Read the complete narrative.
Want to see what kind of revenue mix, margin profile, and future valuation multiple Tokyo uses to get to that fair value? The narrative spells out a detailed path from recurring procedure volumes to cash flows and then translates that into a premium pricing framework that differs from headline P/E ratios.
Result: Fair Value of $532.46 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this fair value story can be challenged if procedure volumes slow, or if hospitals delay capital and service spending on new and existing da Vinci systems.
Find out about the key risks to this Intuitive Surgical narrative.
Another View: Earnings Multiple Paints a Richer Price Picture
Tokyo’s narrative suggests Intuitive Surgical trades around a 14% discount to a US$532.46 fair value, yet the market is pricing the stock on a P/E of 54.4x, compared with 23.6x for the US Medical Equipment industry, 26.1x for peers, and a fair ratio of 32.1x.
Story Continues
That gap signals investors are paying a substantial premium for Intuitive Surgical’s earnings, which can magnify both upside and downside if expectations change. How comfortable are you with paying nearly double the sector’s earnings multiple for this story?
See what the numbers say about this price — find out in our valuation breakdown.NasdaqGS:ISRG P/E Ratio as at May 2026
Next Steps
With the stock carrying a rich P/E and mixed recent returns, sentiment is clearly split. Move quickly, review the key drivers, and then weigh the 3 key rewards.
Looking for more investment ideas?
If Intuitive Surgical is already on your radar, now is the time to broaden your watchlist so you are not missing other compelling opportunities.
Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems that combine quality fundamentals with less crowded investor attention. Strengthen your portfolio’s foundation by reviewing the solid balance sheet and fundamentals stocks screener (44 results) and focusing on companies with healthier finances. Target resilient cash returns by checking out the 13 dividend fortresses that prioritise higher yields with a focus on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ISRG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?
May 3, 2026
Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on Rijnberk InvestInsights’s Substack by Daan | InvestInsights. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.'s share was trading at $451.29 as of April 21st. ISRG’s trailing and forward P/E were 59.16 and 46.51 respectively according to Yahoo Finance.Is Intuitive Surgical’s (ISRG) Valuation Limiting Further Upside After Earnings?
Master Video/Shutterstock.com
Intuitive Surgical (ISRG) is a global leader in robotic-assisted surgery, combining advanced robotics, 3D visualization, and precision instruments to enable minimally invasive procedures, and has established a dominant position with 70–80% market share in soft-tissue robotics. The company operates a highly durable razor-and-blade model, where roughly 85% of revenue is recurring from instruments, accessories, and service contracts, creating strong visibility, high margins, and long-term compounding potential.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Its installed base exceeds 11,000 systems, with over 3.1 million procedures performed in 2025 alone, reflecting sustained high-teens growth driven by increasing adoption, higher utilization, and expanding clinical indications. Recent innovations, particularly the da Vinci 5 platform, are enhancing system capabilities, unlocking new procedures such as cardiac surgery, and introducing software-driven upgrades and subscription layers that further deepen recurring revenue streams. Despite emerging competition and localized pressure in China, Intuitive’s moat remains significant, supported by switching costs, extensive clinical data, surgeon training ecosystems, and unmatched procedural breadth.
Financially, the company delivered strong 2025 results with 21% revenue growth, expanding margins, and $2.5 billion in free cash flow, supported by a pristine balance sheet with $9 billion in cash and no debt. While shares have corrected meaningfully, the underlying business remains resilient with a long runway, as less than 5% of eligible surgeries globally are performed robotically.
This creates a compelling long-term opportunity, with consistent double-digit growth driven by demographic tailwinds, rising surgical volumes, and continued technological advancement, positioning Intuitive Surgical as a best-in-class compounder in healthcare.
Previously, we covered a bullish thesis on Intuitive Surgical, Inc. (ISRG) by Kontra Investment Xchange in December 2024, which highlighted the company’s leadership in robotic surgery, strong da Vinci adoption, and long-term growth driven by low market penetration and expanding applications. ISRG’s stock price has depreciated by approximately 16.73% since our coverage. Daan | InvestInsights shares a similar view but emphasizes on recurring revenue strength and da Vinci 5 innovation.
Story Continues
Intuitive Surgical, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 109 hedge fund portfolios held ISRG at the end of the fourth quarter which was 99 in the previous quarter. While we acknowledge the risk and potential of ISRG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ISRG and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
View Comments
- Jim Cramer Believes Competitors Might Hurt Intuitive Surgical
May 3, 2026
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said:
Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit pay dirt, and that is going to hurt Intuitive Surgical.
Photo by Adam Nowakowski on Unsplash
Intuitive Surgical, Inc. (NASDAQ:ISRG) designs and manufactures robotic systems and instruments that enable minimally invasive surgical and diagnostic procedures. During the March 19 episode, a caller asked which metric is the most important for the company. In response, Cramer commented:
It’s hospital utilization, and what gets me down here is that the stock, the earnings are good, but the multiple is too high. And when I say that, you have to go back to How to Make Money in Any Market. My book spends a lot of time about the idea that, you know what, if the multiple’s too high, it doesn’t matter what the sales are and the earnings [are], it’s just not going to be able to go higher. And that’s going on with Intuitive. It’s just gotten too expensive per share.
While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Apr 29, 2026
Intuitive Surgical’s ISRG first-quarter 2026 performance reflects a nuanced international picture — strong overall OUS (outside U.S.) procedure growth, but with emerging pockets of weakness, particularly in China and Japan. While international markets remain a key pillar of long-term expansion, recent trends highlight increasing exposure to policy and macro-driven variability.
China remains the most prominent source of near-term pressure. Management pointed to slower tender activity, intensified pricing pressure and rising competition from domestic players, all of which are adversely impacting system placements and near-term growth visibility. The tender-based procurement system inherently introduces volatility, and the growing preference for local manufacturers further complicates Intuitive Surgical’s positioning. These dynamics suggest that China may transition into a structurally more competitive and lower-margin market, even if long-term procedure demand remains intact.
In Japan, the challenge is less about competition and more about capital constraints within hospital systems, which are delaying system adoption. However, the outlook here appears more constructive. Management highlighted an improving reimbursement environment, which could gradually unlock demand and support future procedure growth. This suggests that Japan’s weakness is more cyclical than structural.
Outside these two markets, international growth remains robust, supported by expanding clinical adoption, training infrastructure and broader access to robotic-assisted surgery. This reinforces the view that global demand fundamentals are intact.
Overall, Intuitive Surgical’s international weakness appears partly temporary and partly structural. While Japan’s headwinds are likely cyclical, China presents a more complex mix of policy risk and competitive intensity. The company’s ability to navigate pricing, local competition and capital constraints will be critical in determining whether international markets remain a consistent growth driver or a source of ongoing volatility.
Peer Updates
DexCom DXCM delivered strong international performance, with revenue outside the United States growing 18% on a reported basis (15% organic) in the fourth quarter of 2025, driven by expanding CGM adoption across Europe, particularly in markets like Germany, the United Kingdom and France. Growth is being fueled by broader reimbursement access, especially in type 2 diabetes, and a tiered product portfolio strategy tailored to local market dynamics. However, challenges persist, including tiered reimbursement systems and slower coverage expansion in certain regions. DexCom is addressing these through increased awareness, product localization and upcoming launches like Stelo internationally, positioning DexCom to sustain double-digit international growth.
Story Continues
Glaukos GKOS is also expanding internationally, with its glaucoma franchise delivering 18% reported growth (13% constant currency), supported by continued adoption of MIGS technologies and infrastructure scaling. Glaukos is driving growth through physician training, market development and broader access initiatives, particularly for its iStent portfolio. However, international markets face competitive headwinds from new product trialing, which are expected to persist into 2026 and may moderate growth rates. Despite this, Glaukos’ differentiated pipeline and recent European launches, such as iStent infinite, provide incremental tailwinds, supporting long-term international expansion.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 17.6% so far this year compared with an 15% decline for the industry.Zacks Investment Research
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 43.35, above the industry average. But it is still lower than its five-year median of 70.45. ISRG carries a Value Score of D.Zacks Investment Research
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies an 15.7% rise from the year-ago period’s level.Zacks Investment Research
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Glaukos Corporation (GKOS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
